Even though pruritus affects a significant number of people with chronic disease, it is rarely adequately treated. Drug therapies often rely on antihistamines, which have not shown to be beneficial in systemic pruritus. Hydroxyzine is frequently used to treat pruritus associated with kidney failure. Since Canada’s sole manufacturer of hydroxyzine is no longer making this product, this is an ideal time to review the mechanisms of itch in advanced organ failure and the specific therapies that give relief. Although there is literature describing itch in patients with cancer, this article is limited to pathogenesis and treatment of systemic itch secondary to chronic, noncancer diseases. We summarize recent systematic reviews, although the studies included in these reviews are often small, and mostly cohort studies.
Get full access to this article
View all access options for this article.
References
1.
FowlerE, YosipovitchG. A new generation of treatments for Itch. Acta Derm Venereol, 2020; 100(2):adv00027; doi: 10.2340/00015555-3347
2.
ChungBY, UmJY, KimJC, et al.Pathophysiology and treatment of pruritus in the elderly. Int J Mol Sci, 2021; 22:174.
3.
PrasadB, GagarinovaM, SharmaA. Five things to know about pruritus in patients on dialysis. Can J Kidney Health Dis, 2023; 10:20543581221149620; doi: 10.1177/20543581221149620
4.
HashimotoT, YosipovitchG. Itching as a systemic disease. J Allergy Clin Immunol, 2019; 144(2):375–380; doi: 10.1016/j.jaci.2019.04.005
5.
PonikowskaM, BiegusJ, ZymlinskiR, SzepietowskiJC. Itch in patients with acute heart failure. Acta Derm Venereol, 2019; 99(7):679–680; doi: 10.2340/00015555-3187
BrennanFP, JoslandE, KellyJJ. Chronic pruritus: Histamine is not always the answer!. J Pain Symptom Manage, 2015; 50(4):566–570; doi: 10.1016/j.jpainsymman.2015.04.009
8.
MahmoudO, OladipoO, MahmoudRH, YosipovitchG. Itch: From the skin to the brain - peripheral and central neural sensitization in chronic itch. Front Mol Neurosci, 2023; 16:1272230; doi: 10.3389/fnmol.2023.1272230
9.
HawroT, PrzybyłowiczK, SpindlerM, et al.The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study. J Am Acad Dermatol, 2021; 84(3):691–700; doi: 10.1016/j.jaad.2020.08.035
10.
KimD, PollockC. Epidemiology and burden of chronic kidney disease-associated pruritus. Clin Kidney J, 2021; 14(Suppl 3):i1–i7; doi: 10.1093/ckj/sfab142
11.
YosipovitchG, RosenJD, HashimotoT. Itch: From mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol, 2018; 142(5):1375–1390; doi: 10.1016/j.jaci.2018.09.005
12.
CetinBM, GuzelFB, OzturkI, et al.The factors that are associated with itching in chronic kidney patients and evaluation of itching with the 5d itch scale. Int Urol Nephrol, 2024; 56(6):1973–1981; doi: 10.1007/s11255-023-03937-y
13.
PhanNQ, BlomeC, FritzF, et al.Assessment of pruritus intensity: Prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol, 2012; 92(5):502–507; doi: 10.2340/00015555-1246
LaveryMJ, StullC, KinneyMO, YosipovitchG. Nocturnal pruritus: The battle for a peaceful night’s sleep. Int J Mol Sci, 2016; 17(3):425; doi: 10.3390/ijms17030425
16.
KoM-J, PengY-S, WuH-Y. Uremic pruritus: Pathophysiology, clinical presentation, and treatments. Kidney Res Clin Pract, 2023; 42(1):39–52; doi: 10.23876/j.krcp.21.189
17.
LauT, LeungS, LauW. Gabapentin for uremic pruritus in hemodialysis patients: A qualitative systematic review. Can J Kidney Health Dis, 2016; 3:107; doi: 10.1186/s40697-016-0107-8
18.
HerczD, JiangSH, WebsterAC. Interventions for itch in people with advanced chronic kidney disease. Cochrane Database Syst Rev, 2020; 12(12):CD011393; doi: 10.1002/14651858.CD011393.pub
19.
JaiswalD, UzansD, HaydenJ, et al.Targeting the opioid pathway for uremic pruritus: A systematic review and meta-analysis. Can J Kidney Health Dis, 2016; 3:2054358116675345; doi: 10.1177/2054358116675345
20.
Pauli-MagnusC, MikusG, AlscherDM, et al.Naltrexone does not relieve uremic pruritus: Results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol, 2000; 11(3):514–519; doi: 10.1681/ASN.V113514
21.
BoehlkeC, JoosL, CouneB, et al.Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database Syst Rev, 2023; 4(2023):CD008320; doi: 10.1002/14651858.CD008320.pub4
MahmudpourM, RoozbehJ, Raiss JalaliGA, et al.Therapeutic effect of montelukast for treatment of uremic pruritus in hemodialysis patients. Iran J Kidney Dis, 2017; 11(1):50–55.
KimJC, ShimWS, KwakSI. Pathogenesis and treatment of pruritis assoc w CKD and cholestasis. J Mol Sci, 2023.
26.
Murray-BrownFL. Naltrexone for cholestatic itch: A systematic review. BMJ Support Palliat Care, 2021; 11(2):217–225; doi: 10.1136/bmjspcare-2020-002801
27.
HegadeVS, KendrickSF, JonesDE. Drug treatment of pruritus in liver diseases. Clin Med (Lond), 2015; 15(4):351–357; doi: 10.7861/clinmedicine.15-4-351
28.
StefaniakA, KrajewskiP, Bednarska-ChabowskaD, et al.Itch in adult population with type 2 diabetes mellitus: Clinical profile, pathogenesis and disease-related burden in a cross-sectional study. Biology (Basel), 2021; 10(12):1332; doi: 10.3390/biology10121332
29.
ShirleyM. Maralixibat: First approval. Drugs, 2022; 82(1):71–76; doi: 10.1007/s40265-021-01649-0
30.
HeA, AlhaririJ, SwerenR, et al.Aprepitant for the treatment of chronic refractory pruritus. Biomed Res Int, 2017; 2017:4790810; doi: 10.1155/2017/4790810
31.
WorthH, O’HaraDV, AgarwalN, et al.Cannabinoids for symptom management in patients with kidney failure: A narrative review. Clin J Am Soc Nephrol, 2022; 17(6):911–921; doi: 10.2215/CJN.11560821
32.
FangXX, WangH, SongHL, et al.Neuroinflammation involved in diabetes-related pain and itch. Front Pharmacol, 2022; 13:921612; doi: 10.3389/fphar.2022.921612
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
